健康新聞
All coverage
- BICALUTAMIDA 相關新聞
- BOSENTAN 相關新聞
- CAPECITABINA 相關新聞
- CLONAZEPAM 相關新聞
- ELTROMBOPAG 相關新聞
- GEFITINIB 相關新聞
- IBRUTINIB 相關新聞
- IBUPROFENO 相關新聞
- LENALIDOMIDA 相關新聞
- LORATADINA 相關新聞
- MEBENDAZOL 相關新聞
- METFORMINA 相關新聞
- MIGLUSTAT 相關新聞
- MISOPROSTOL 相關新聞
- PARACETAMOL 相關新聞
About the Developer
This platform is developed and operated by 藥提醒科技有限公司 (yao.care, company registration number 83620786, 12F, No. 220, Sec. 2, Taiwan Blvd., West Dist., Taichung City, Taiwan).
ARTxGNN is the Argentina site of the company's "TxGNN Drug Repurposing" product line.
The same system is deployed across 30 countries and regions, each named {CC}TxGNN
(JpTxGNN, UsTxGNN, DETxGNN, and so on) at {cc}txgnn.yao.care.
Product overview: https://www.yao.care/medical/txgnn/.
The TxGNN model itself was developed by the Zitnik Lab at Harvard Medical School and published in Nature Medicine. This platform is the production system 藥提醒科技有限公司 built on top of that model, covering national drug-registration data integration, dual knowledge-graph and deep-learning prediction, PubMed / ClinicalTrials evidence grading, and SMART on FHIR electronic health record integration.
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)